Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schreeder

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Primary Care|March 1, 1988
Viral hepatitisM Schreeder
European Journal of Immunology|November 11, 2008
FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemiaDaniel M Schreeder, Jicun Pan, Fu Jun Li, et al.
European Journal of Immunology|July 17, 2013
FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiationFu Jun Li, Daniel M Schreeder, Ran Li, et al.
American Journal of Clinical Oncology|August 1, 1988
Phase I-II study of cisplatin, VP-16, MGBG, mitomycin, and vinblastine with radiation therapy for non-small-cell lung cancerE S Christian, M Schreeder, M M Salter, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 4, 2010
Cutting edge: FcR-like 6 is an MHC class II receptorDaniel M Schreeder, John P Cannon, Jiongru Wu, et al.
Advances in Experimental Medicine and Biology|March 7, 2007
Fc receptor-like proteins (FCRL): immunomodulators of B cell functionGötz R A Ehrhardt, Chuen-Miin Leu, Shuangyin Zhang, et al.
JCI Insight|December 21, 2018
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagementDouglas B Johnson, Mellissa J Nixon, Yu Wang, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Primary Care|March 1, 1988
Viral hepatitisM Schreeder
European Journal of Immunology|November 11, 2008
FCRL6 distinguishes mature cytotoxic lymphocytes and is upregulated in patients with B-cell chronic lymphocytic leukemiaDaniel M Schreeder, Jicun Pan, Fu Jun Li, et al.
European Journal of Immunology|July 17, 2013
FCRL3 promotes TLR9-induced B-cell activation and suppresses plasma cell differentiationFu Jun Li, Daniel M Schreeder, Ran Li, et al.
American Journal of Clinical Oncology|August 1, 1988
Phase I-II study of cisplatin, VP-16, MGBG, mitomycin, and vinblastine with radiation therapy for non-small-cell lung cancerE S Christian, M Schreeder, M M Salter, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 4, 2010
Cutting edge: FcR-like 6 is an MHC class II receptorDaniel M Schreeder, John P Cannon, Jiongru Wu, et al.
Advances in Experimental Medicine and Biology|March 7, 2007
Fc receptor-like proteins (FCRL): immunomodulators of B cell functionGötz R A Ehrhardt, Chuen-Miin Leu, Shuangyin Zhang, et al.
JCI Insight|December 21, 2018
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagementDouglas B Johnson, Mellissa J Nixon, Yu Wang, et al.
Pageof 1